Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 13/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22127777 | 1.00 | CMA1 (0.52) | CMA1ITGB3ITGA2BMALT1REN | |
| SCHEMBL22127775 | 1.00 | CMA1 (0.52) | CMA1ITGB3ITGA2BMALT1REN | |
| SCHEMBL22127929 | 1.00 | CMA1 (0.52) | CMA1ITGB3ITGA2BMALT1REN | |
| SCHEMBL22127925 | 1.00 | CMA1 (0.52) | CMA1ITGB3ITGA2BMALT1REN | |
| SCHEMBL13323704 | 1.00 | CMA1 (0.52) | CMA1ITGB3ITGA2BMALT1REN | |
| SCHEMBL22127976 | 0.96 | CMA1 (0.53) | CMA1ITGB3ITGA2BMALT1REN | |
| SCHEMBL22127864 | 0.96 | CMA1 (0.53) | CMA1ITGB3ITGA2BMALT1REN | |
| SCHEMBL22127868 | 0.96 | CMA1 (0.53) | CMA1ITGB3ITGA2BMALT1REN | |
| SCHEMBL22127865 | 0.96 | CMA1 (0.53) | CMA1ITGB3ITGA2BMALT1REN | |
| SCHEMBL22127978 | 0.96 | CMA1 (0.53) | CMA1ITGB3ITGA2BMALT1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988561-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| EP-3988561-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2022-04-27 | — | — | EP | disclosed |
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | XWPharma Ltd. (KY) | 2022-04-26 | — | — | US | disclosed |
| EP-3679051-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2021-12-29 | — | — | EP | disclosed |
| US-20210061791-A1 | REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES | XWPharma Ltd. (KY) | 2021-03-04 | — | — | US | disclosed |
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | XW LABORATORIES INC. (KY) | 2021-01-12 | — | — | US | disclosed |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | CMA1 2018/4885ITGB3 4306/4885ITGA2B 3780/4885 |
| US-20210061791-A1 | REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES | GSR, TXNRD2, GPX1 | CMA1 2018/4885ITGB3 4306/4885ITGA2B 3780/4885 |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | GPX1, SOD1, GPX4 | CMA1 2006/4885ITGB3 4136/4885ITGA2B 3243/4885 |
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | CMA1 2018/4885ITGB3 4306/4885ITGA2B 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.